

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA.

Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

## **Epigenomics AG sets subscription price at EUR 1.11 per new share**

**Berlin, 31 October 2019** – The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY; the “Company”) resolved today, with approval of the Supervisory Board, to set the subscription price per new share at EUR 1.11 as part of the capital increase resolved on 17 October 2019. The subscription price represents a discount of approximately 10% to the volume-weighted average price for one share of the Company on the electronic trading system XETRA on the Frankfurt Stock Exchange (*Frankfurter Wertpapierbörse*) from the beginning of the subscription period on 24 October 2019 until close of trading on 30 October 2019.

The new shares are offered to the shareholders of the Company as part of a public offering in Germany by way of indirect subscription rights during the subscription period from 24 October 2019 until 6 November 2019. The subscription ratio is 10:3. This means that for each ten existing shares in the Company, subscription rights for three new shares are allocated. New shares that are not subscribed during the subscription period shall be offered to selected qualified investors as part of an international private placement.

### **Contact:**

#### **Company**

Epigenomics AG  
Geneststraße 5  
10829 Berlin  
T +49 (0) 30 24345 0  
F +49 (0) 30 24345 555  
Email: [ir@epigenomics.com](mailto:ir@epigenomics.com)

### **Investor Relations**

IR.on AG  
Frederic Hilke, Fabian Kirchmann  
T +49 221 9140 970  
Email: [ir@epigenomics.com](mailto:ir@epigenomics.com)

## **Important Notice**

*This publication does not constitute or form part of, and should not be construed as an offer or an invitation to sell, or issue or the solicitation of any offer to buy or subscribe for, any securities. The shares will be solely offered on the basis of the published subscription offer and the prospectus approved by the German Federal Financial Supervisory Authority (BaFin – Bundesanstalt für Finanzdienstleistungsaufsicht). The prospectus was published on the Company's website at [www.epigenomics.com](http://www.epigenomics.com) after approval by BaFin on October 18, 2019. The subscription offer was published on October 21, 2019.*

*This publication does, in particular, not constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the laws of any state within the U.S., and may not be offered or sold in the United States or to or for the account or benefit of U.S. persons, except that the offered shares may be offered or sold to qualified institutional buyers in reliance on certain exemptions from the registration requirements of the Securities Act and applicable state securities laws. This publication and the information contained herein may not be distributed or sent into the United States, or in any other jurisdiction in which offers or sales of the securities described herein would be prohibited by applicable laws, and should not be distributed to United States persons or by way of publications with a general circulation in the United States. No public offering of the shares is being made in the United States. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The securities referred to herein have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan.*

## **Forward-Looking Statements**

*This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*